Why are we still missing patients despite having the data, the solutions, and the intent? This panel explores why early intervention remains so difficult in practice, and what needs to change for that to shift. With four different perspectives, we'll examine the systemic blind spots that leave patients unidentified, the collaborations needed to reduce friction across the patient journeys, and the persistent gap between data and action.

As the industry moves beyond one-size-fits-all approaches, the treatment phase of the patient journey is being redefined. This session explores the emerging strategies bringing greater precision - and greater relevance - to how therapies are developed and delivered. Alexandra Toader examines how advances in predictive modeling and adaptive research design are beginning to shift that calculus, and what that means for the future of treatment.

While data and AI solutions are widely discussed, what's harder to navigate is the organisational reality - the gap between strategy and execution, and between intent and the way decisions are actually made inside complex institutions. This closing session brings together perspectives from across life science to reflect on what industry-wide change looks like in practice, and what it demands of the leaders and structures trying to drive it forward.